Tinzaparin in cancer associated thrombosis beyond 6months: TiCAT study
| Autor: | Teresa Elias-Hernandez, Maribel Asensio-Cruz, Emilio Montero-Romero, Silvia Navarro-Herrero, Luis Jara-Palomares, Maria Pilar Serrano-Gotarredona, Isabel Blasco-Esquivias, Lucia Marin-Barrera, Juan Manuel Praena-Fernández, Remedios Otero, Aurora Solier-Lopez, Maria Rodriguez de la Borbolla-Artacho, Carlos Palacios, Jose Maria Sanchez-Diaz |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Male
medicine.medical_specialty Time Factors medicine.drug_class Low molecular weight heparin 030204 cardiovascular system & hematology 03 medical and health sciences 0302 clinical medicine Tinzaparin Fibrinolytic Agents Internal medicine Neoplasms medicine Humans Prospective Studies Low-molecular-weight heparin Cancer business.industry Incidence (epidemiology) Pulmonary embolism Hazard ratio Thrombosis Hematology Heparin Heparin Low-Molecular-Weight Middle Aged medicine.disease Confidence interval Surgery 030220 oncology & carcinogenesis Female business Venous thromboembolism medicine.drug |
| Zdroj: | Thrombosis research. 157 |
| ISSN: | 1879-2472 |
| Popis: | Introduction The safety and efficacy of low-molecular-weight heparin (LMWH) treatment in patients with cancer-associated thrombosis (CAT) beyond 6 months are unknown. Our aim was to determine the safety of long-term tinzaparin use in patients with CAT. Methods We performed a prospective, open, single arm, multicentre study in patients with CAT receiving treatment with tinzaparin. We evaluated the rate of clinically relevant bleeding events (major and non-major clinically relevant bleeding) and venous thromboembolism (VTE) recurrence. Results A total of 247 patients were recruited, with a crude incidence of major bleeding of 4.9% (12/247). The rate of clinically relevant bleeding during months 1–6 and 7–12, was 0.9% [95% confidence interval (95% CI) 0.5 to 1.6%] and 0.6% (95% CI 0.2 to 1.4%) (p = 0.5) per patient and month, respectively. Male gender showed greater risk for clinically relevant bleeding with a hazard ratio (HR) of 2.97 (95% CI 1.01 to 8.1; p = 0.02). The incidence of VTE recurrence at months 1–6 and 7–12 was 4.5% (95% CI 2.2 to 7.8%) and 1.1% (95% CI 0.1 to 3.9%), respectively. One patient died due to VTE recurrence and two because of severe bleeding. Conclusions Treatment with tinzaparin beyond 6 months is safe in patients with CAT. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect